Acute Graft Versus Host Disease - 162 Studies Found
| Active, not recruiting |
: Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant :
|
| Active, not recruiting |
: Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation :
: 2007-11-21 :
|
| Completed |
: Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT) : Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies : 2014-07-17 :
|
| Completed |
: Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD : Graft Versus Host Disease : 2016-06-28 : Biological: Mesenchymal Stem Cells Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded |
| Completed |
: Preemptive Adoptive CMV-CTL Infusion to Prevent Refractory CMV Infection Post Haplo-HSCT : CMV Infection : 2016-11-28 : Biological: Donor-derived CMVpp65-specific T cells About 1 million per kg CMVpp65-specific T cells will |
| Completed |
: Ruxolitinib for Steroid-refractory GVHD : Graft Vs Host Disease : 2016-12-14 : Drug: Ruxolitinib Oral Tablet Dose reduction criteria for |
| Withdrawn |
: Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation : Hematologic Malignancies : 2013-06-17 : Drug: TXA127 Injection, 300mcg/kg/day for 28 days |
| Enrolling by invitation |
: Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease : Graft-Versus-Host Disease : 2014-07-11 |
| Completed |
: Treatment of Steroid Resistant GVHD by Infusion MSC : Graft-versus-host-disease : 2009-01-20 : Biological: MSC (hPPL) Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD |
| Completed |
: Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX :
: 2006-08-03 :
|